• Patients with histologically proven metastatic colorectal cancer in progression after previous standard treatments (5FU, CPT11 (Irinotecan), oxaliplatin, anti-VEGF (vascular endothelial growth factor), trifluridine/tipiracil, anti-EGFR (epidermal growth factor receptor) therapy if KRAS (Kirsten rat sarcoma) and NRAS WT (wild type), anti-BRAF therapy if BRAF V600E mutated, and anti-PD1 (Programmed Death-1) if MSI-H (microsatellite instability) /dMMR (deficient MisMatch Repair) tumor, or not considered as candidate for these treatments.

• Life expectancy of at least 3 months

• Female or male with age \>18 years old

• Performance status = 0 or 1 (Annex 1)

• Measurable disease defined according to RECIST v1.1 guidelines (scanner or MRI)

• Adequate bone marrow, liver and renal functions.

∙ Haemoglobin ≥ 9 g/dL; absolute neutrophil count (ANC) ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L

‣ Total serum bilirubin ≤ 1.5 times upper normal value (ULN), serum alkaline phosphatase \< 5 times ULN, aminotransferases (AST/ALT) ≤ 3 × ULN in absence of hepatic metastasis or ≤ 5 if presence of hepatic lesions

‣ Cockcroft glomerular filtration rate \> 50 ml/min

‣ Proteinuria \<2+ (dipstick urinalysis) or ≤1g/24hour

• No contraindication to Iodine contrast media injection during CT

• For female patients of childbearing potential, negative pregnancy test within 14 days before starting the study drug. Men and women are required to use adequate birth control during the study (when applicable),

• Signed and dated informed consent,

⁃ Ability to comply with the study protocol, in the Investigator's judgment.

⁃ Registration in a national health care system (CMU included).